Neurosense Therapeutics Ltd. (NRSN) has released an update.
NeuroSense Therapeutics Ltd., a biotech firm specializing in neurodegenerative disease treatments, has been notified of its potential delisting from the Nasdaq due to non-compliance with stockholders’ equity requirements. The company plans to appeal the decision by requesting a hearing, which will delay any delisting action. NeuroSense is focused on addressing major diseases such as ALS, Alzheimer’s, and Parkinson’s, with limited current treatment options.
For further insights into NRSN stock, check out TipRanks’ Stock Analysis page.
